Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8418104 | Journal of Immunological Methods | 2013 | 10 Pages |
Abstract
Various aspects of the human immune system can be analyzed to determine the efficacy of a vaccine. We have developed a B-cell ELISpot to measure HIV-specific antibody-secreting B cells in the peripheral blood as a result of vaccination or natural infection. Our method includes stimulating peripheral blood mononuclear cells with interleukin-2 and a polyclonal activator, R848, to induce memory B cells to differentiate into antibody-secreting cells. Total immunoglobulin-secreting as well as antigen-specific B cells are then quantified. We have tested several HIV Env gp120 and gp140 proteins from different HIV subtypes, as well as a sensitive consensus group M Env gp140. Our findings indicate that the B-cell ELISpot provides a sensitive and specific tool to detect antigen-specific memory B-cell responses, and it is equally suited to detect antibody-secreting plasmablasts present in the circulation shortly after infection or vaccination.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Paula N. Walsh, David P. Friedrich, Julie A. Williams, Rebecca J. Smith, Terri L. Stewart, Donald K. Carter, Hua-Xin Liao, M. Juliana McElrath, Nicole Frahm, The NIAID HIV Vaccine Trials Network The NIAID HIV Vaccine Trials Network,